Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model-Reference-Cited by-同舟云学术

Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model

Published:2020-07 Issue:3 Volume:10 Page:1-10
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Sanada Takayuki J.¹²^ORCID,Hosomi Koji³,Shoji Hiroki¹,Park Jonguk⁴,Naito Akira¹,Ikubo Yumiko¹,Yanagisawa Asako¹,Kobayashi Takayuki¹,Miwa Hideki¹,Suda Rika¹,Sakao Seiichiro¹^ORCID,Mizuguchi Kenji⁴⁵,Kunisawa Jun³,Tanabe Nobuhiro¹⁶,Tatsumi Koichiro¹

Affiliation:

1. Department of RespirologyGraduate School of MedicineChibaJapan

2. Department of PulmonologyInstitute for Cardiovascular Research (ICaR‐VU)/VU University Medical CenterAmsterdamthe Netherlands

3. Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental SystemNational Institutes of Biomedical Innovation, Health, and NutritionOsakaJapan

4. Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health, and NutritionOsakaJapan

5. Institute for Protein ResearchOsaka UniversityOsakaJapan

6. Department of RespirologyChibaken Saiseikai Narashino HospitalNarashinoJapan

Funder

Japan Society for the Promotion of Science

Ministry of Health, Labour and Welfare

Japan Agency for Medical Research and Development

the Ministry of Health, Labour, and Welfare of Japan and to the Pulmonary Hypertension Research Group of the Japan Agency for Medical Research and Development

the Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2045894020929147

Reference51 articles.

1. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives;Humbert M;Eur Respir J,2019

2. Primary pulmonary hypertension: natural history and the importance of thrombosis;Fuster V;Circulation,1984

3. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension;Humbert M;Eur Respir J,2010

4. Five‐year outcomes of patients enrolled in the REVEAL Registry;Farber HW;Chest,2015

5. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT);Galiè N;Eur Heart J,2015

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of the ACE2-Ang-(1-7)-Mas axis on gut flora diversity and intestinal metabolites in SuHx mice;Frontiers in Microbiology;2024-08-23

2. Disease-associated gut microbiome and metabolome changes in rats with chronic hypoxia-induced pulmonary hypertension;Frontiers in Cell and Developmental Biology;2024-07-12

3. Salvia miltiorrhiza bunge extract improves the Th17/Treg imbalance and modulates gut microbiota of hypertensive rats induced by high-salt diet;Journal of Functional Foods;2024-06

4. Microbiota and pulmonary hypertension: a systematic review on human studies;2024-04-22

5. Extrapulmonary manifestations of pulmonary arterial hypertension;Expert Review of Respiratory Medicine;2024-04-02